Authorization

VistaGen, Nuformix Enter Collaboration In CNS Therapeutics - Quick Facts

(RTTNews) - VistaGen Therapeutics (VTGN) and Nuformix plc (NFX.L) have agreed to develop cocrystal-based formulations of VistaGen's CNS product candidates. VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs. It is targeting high-value unmet needs via drug repurposing with a lead programme in fibrosis.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031